Apimeds, FDA to Discuss Bee Venom Treatment for Osteoarthritis

Dow Jones

Yesterday

By Amira McKee

Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration.

The pharmaceutical company, along with L kahi Therapeutics, said Wednesday that the meeting will be held May 4, and represents an important step in its U.S. regulatory strategy for the treatment, LT-100.

LT-100 is pure honeybee venom originally developed and approved in South Korea, the companies said. Apimeds and L kahi plan to advance the program in the U.S. by integrating historical data with development standards.

"LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress," President of Apimeds and Chief Executive Officer of L kahi Therapeutics Erik Emerson said.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 11, 2026 17:48 ET (22:48 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2610796786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610796786\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610796786?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610796786","market":"sg","top_or_hot":-1,"title":"Apimeds, FDA to Discuss Bee Venom Treatment for Osteoarthritis","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration. \n</p>\n<p>\n  The pharmaceutical company, along with L kahi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, said Wednesday that the meeting will be held May 4, and represents an important step in its U.S. regulatory strategy for the treatment, LT-100. \n</p>\n<p>\n  LT-100 is pure honeybee venom originally developed and approved in South Korea, the companies said. Apimeds and L kahi plan to advance the program in the U.S. by integrating historical data with development standards. \n</p>\n<p>\n  \"LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress,\" President of Apimeds and Chief Executive Officer of L kahi Therapeutics Erik Emerson said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 11, 2026 17:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apimeds, FDA to Discuss Bee Venom Treatment for Osteoarthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApimeds, FDA to Discuss Bee Venom Treatment for Osteoarthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-12 06:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration. \n</p>\n<p>\n  The pharmaceutical company, along with L kahi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, said Wednesday that the meeting will be held May 4, and represents an important step in its U.S. regulatory strategy for the treatment, LT-100. \n</p>\n<p>\n  LT-100 is pure honeybee venom originally developed and approved in South Korea, the companies said. Apimeds and L kahi plan to advance the program in the U.S. by integrating historical data with development standards. \n</p>\n<p>\n  \"LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress,\" President of Apimeds and Chief Executive Officer of L kahi Therapeutics Erik Emerson said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 11, 2026 17:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610796786","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610796786","pubTimestamp":1770850080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration.The pharmaceutical company, along with L kahi Therapeutics, said Wednesday that the meeting will be held May 4, and represents an important step in its U.S. regulatory strategy for the treatment, LT-100.LT-100 is pure honeybee venom originally developed and approved in South Korea, the companies said. Apimeds and L kahi plan to advance the program in the U.S. by integrating historical data with development standards.\"LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress,\" President of Apimeds and Chief Executive Officer of L kahi Therapeutics Erik Emerson said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APUS":"Apimeds Pharmaceutical  U.S, Inc."},"translate_title":"Apimeds与FDA讨论蜂毒治疗骨关节炎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APUS":0.9},"content_text":"By Amira McKee \n\n\n \n\n\n  Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration. \n\n\n  The pharmaceutical company, along with L kahi Therapeutics, said Wednesday that the meeting will be held May 4, and represents an important step in its U.S. regulatory strategy for the treatment, LT-100. \n\n\n  LT-100 is pure honeybee venom originally developed and approved in South Korea, the companies said. Apimeds and L kahi plan to advance the program in the U.S. by integrating historical data with development standards. \n\n\n  \"LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress,\" President of Apimeds and Chief Executive Officer of L kahi Therapeutics Erik Emerson said. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2026 17:48 ET (22:48 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}